<DOC>
	<DOCNO>NCT01544309</DOCNO>
	<brief_summary>The purpose study compare effect rosuvastatin atorvastatin lipid lower effect glucose metabolism hypercholesterolemia patient diabetes mellitus .</brief_summary>
	<brief_title>LIpid Lowering With Highly Potent Statins Hyperlipidaemia With Type 2 Diabetes patiENts</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Hypercholesterolemia patient • Patients achieve target control level LDLC `` Japan Atherosclerosis Society Guidelines Prevention Atherosclerotic Cardiovascular Diseases 2007 '' 2 . Type 2 diabetes patient Patients diagnose type 2 diabetes receive diet therapy , exercise therapy , medication Patients receive constant therapy three month registration plan therapy change Patients keep HbA1c level ( Japan Diabetes Society [ JDS ] level ) le 7.0 % ( , National Glycohemoglobin Standardization Program [ NGSP ] level le 7.4 % ) within three month registration Patients receive receive medication present 3 . Patients give voluntary write consent participate study 4 . Male female patient 20 year old 1 . Patients administer rosuvastatin , atorvastatin ezetimibe within three month registration 2 . Patients severe hypertension ( systolic blood pressure [ SBP ] ≥ 180 mmHg diastolic blood pressure [ DBP ] ≥ 110 mmHg ) 3 . Patients type 1 diabetes 4 . Patients judge familial hypercholesterolemia 5 . Patients serum triglyceride level ≥ 400 mg/dL 6 . Patients onset cardiovascular cerebrovascular disease within three month 7 . Patients serious heart failure ( NYHA classification III IV ) 8 . Patients history hypersensitivity statins 9 . Patients history druginduced myopathy 10 . Patients severe complication diabetes 11 . Patients receive insulin 12 . Patients serious liver kidney disease 13 . Patients serious concurrent disease malignancy , patient severely limit lifespan 14 . Patients may pregnant 15 . Patients judge investigator ineligible participation study reason</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>